← Back to Search

Stem Cell Therapy

Group D for Acute Lymphoblastic Leukemia (HPDSC Trial)

Phase 1
Waitlist Available
Led By Mitchell S Cairo, MD
Research Sponsored by New York Medical College
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

HPDSC Trial Summary

This study is evaluating whether a stem cell transplant can be safely combined with a stem cell transplant from umbilical cord blood and human placental-derived stem cells.

Eligible Conditions
  • Acute Lymphoblastic Leukemia
  • Amegakaryocytic Thrombocytopenia
  • Wolman Disease
  • Metachromatic Leukodystrophy
  • Krabbe Disease
  • Gaucher Disease
  • Aplastic Anemia
  • Adrenoleukodystrophy
  • Fucosidosis
  • Maroteaux-Lamy Syndrome
  • Myelodysplastic Syndrome
  • Acute Myeloid Leukemia
  • Batten Disease
  • Diamond-Blackfan Anemia
  • Niemann-Pick Disease
  • Hurler Syndrome

HPDSC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety
Secondary outcome measures
Mortality
Relapse
Survival
+2 more

HPDSC Trial Design

4Treatment groups
Experimental Treatment
Group I: Group DExperimental Treatment1 Intervention
double unrelated cord blood units with ≥4/6 HLA match to patient and each other and unrelated HPDSC
Group II: Group CExperimental Treatment1 Intervention
unrelated cord blood with ≥4/6 HLA match to the patient but related to HPDSC
Group III: Group BExperimental Treatment1 Intervention
unrelated cord blood with ≥ 4/6 HLA match to the patient and unrelated HPDSC
Group IV: Group AExperimental Treatment1 Intervention
related cord blood with ≥3/6 HLA match to the patient and related HPDSC
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Human Placental Derived Stem Cell
2013
Completed Phase 1
~50

Find a Location

Who is running the clinical trial?

New York Medical CollegeLead Sponsor
70 Previous Clinical Trials
6,090 Total Patients Enrolled
Mitchell S Cairo, MDPrincipal InvestigatorNew York Medical College
14 Previous Clinical Trials
1,125 Total Patients Enrolled
~4 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top